“We are dedicating the next ten years to the company’s mission of doing good, with plans for the future focusing on boosting innovation capacity and expanding Biofarm to Africa, southeastern Asia and Europe, which will implicitly lead to a positive turnover evolution and rising opportunities for subsequent expansion,” said Catalin Vicol, the company’s general manager.
He added Romania will continue to be a business environment favorable to Biofarm’s further development.
Biofarm is owned by SIF Muntenia (51%) and SIF Banat-Crisana (36.7%). The drug manufacturer has a RON815 million capitalization.
(English version by Catalina Apostoiu)